This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
The Grail Galleri test, which can screen for 50 types of cancer from a single blood draw, has garnered significant attention in the medical community. However, its path to widespread adoption is being hindered by uncertainty over insurance coverage, which is contingent upon approval from the US Food and Drug Administration (FDA). The test's developer, Grail, will need to address concerns raised by a major study that failed to demonstrate the test's efficacy in detecting later-stage cancers.
The stakes are high, as a positive FDA review could pave the way for Medicare and other health insurers to cover the test, making it more accessible to a broader population. Currently, the test is available for purchase, but its cost - around $900 - may be prohibitively expensive for many individuals. If approved and covered by insurance, the Galleri test could become a game-changer in cancer detection, potentially saving lives and reducing treatment costs in the long run.
Industry watchers will be closely monitoring the FDA's decision on the Galleri test, as well as the results of further studies aimed at addressing the test's limitations. Key factors to watch include the FDA's assessment of the test's clinical utility and the design of future studies to validate its effectiveness in real-world settings. Additionally, investors will be keeping a close eye on Grail's progress, as the company's success is closely tied to the test's adoption and reimbursement by insurers.
Originally reported by marketwatch.com. ExpoNews adds analysis for finance & markets readers.